Mainz Biomed Sees Surge in Demand for Enhanced ColoAlert Screening

Mainz Biomed N.V., a company specializing in molecular genetics diagnostics, reports a growing demand for its enhanced ColoAlert, a colorectal cancer screening test. Launched in July 2024, the product is being adopted across Europe and select global markets. Existing partners are transitioning to this new version, citing its efficiency and improved user experience.

GANZIMMUN Diagnostics, a leading German laboratory, will fully implement the enhanced ColoAlert by early next year. This decision reflects the product's advancements in sample processing and user-friendliness, which have established a new industry benchmark.

The enhanced version features a proprietary DNA stabilizing buffer and streamlined collection devices. These innovations minimize the need for retesting and cut turnaround times to 2-3 days.

GANZIMMUN will promote the updated ColoAlert at the 57th Medizinische Woche Baden-Baden, highlighting its role in early cancer detection and complementary medicine. Mainz Biomed sees this event as an opportunity to demonstrate the test’s effectiveness in the early detection of colorectal cancer.